AI Article Synopsis
- Fenoldopam mesylate is a medication mainly used for severe hypertension and has potential protective effects on the kidneys due to its action on DA-1 receptors found in high density in renal tissues.
- Research shows that Fenoldopam mesylate can effectively reduce the risk of postoperative Acute Kidney Injury (AKI) when administered before damage occurs, and it has also shown positive effects for ICU patients with AKI, despite limited studies.
- Results regarding its efficacy in preventing contrast-induced nephropathy have been mixed, indicating that further investigation is needed in this area.
Article Abstract
Background: Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated.
Methods: We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced nephropathy.
Results: Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples.
Conclusion: Conflicting results were achieved in contrast-induced nephropathy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751352 | PMC |
| http://dx.doi.org/10.2174/1389201020666190417124711 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fenoldopam for preventing and treating acute kidney injury.
Cochrane Database Syst Rev
November 2024
Cochrane Kidney and Transplant, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia.
Article Synopsis
- Fenoldopam is a drug that selectively activates dopamine A1 receptors, increasing kidney blood flow, and it's being evaluated for its effectiveness and safety in preventing and treating acute kidney injury (AKI) in both adults and children.
- The review examined randomized controlled trials (RCTs) involving fenoldopam related to AKI caused by surgery, radiocontrast exposure, or sepsis, using rigorous data collection and analysis methods.
- A total of 25 RCTs were identified, involving 3,339 participants, indicating a substantial body of research focused on fenoldopam's impact on AKI.
Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment.
Front Psychiatry
October 2024
Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
For over seven decades, dopamine receptor 2 (D receptor) antagonists remained the mainstay treatment for neuropsychiatric disorders. Although it is effective for treating hyperdopaminergic symptoms, it is often ineffective for treating negative and cognitive deficits. Trace amine-associated receptor 1 (TAAR1) is a novel, pharmacological target in the treatment of schizophrenia and other neuropsychiatric conditions.
View Article and Find Full Text PDFFenoldopam for Renal Protection in Cardiac Surgery: Pharmacology, Clinical Applications, and Evolving Perspectives.
J Clin Med
October 2024
Faculty of Medicine and Surgery, Kore University, 94100 Enna, Italy.
This comprehensive review examines the role of Fenoldopam, a selective dopamine-1 receptor agonist, in preventing and treating acute kidney injury (AKI) during cardiac surgery. AKI remains a significant complication in cardiac surgery, associated with increased morbidity, mortality, and healthcare costs. The review explores Fenoldopam's pharmacological properties, mechanism of action, and clinical applications, synthesizing evidence from randomized controlled trials, meta-analyses, and observational studies.
View Article and Find Full Text PDFEfficacy and safety of fenoldopam for the treatment of hypertensive crises in children with kidney disease: a retrospective study.
Pediatr Nephrol
January 2025
Pediatric Nephrology Unit, Department for Women's and Children's Health, University-Hospital of Padua, Padua, Italy.
Background: Hypertensive crises in children represent critical medical situations characterized by severe hypertension and potential organ damage. Fenoldopam, a dopaminergic medication, offers a viable therapeutic option for managing such clinical scenarios. We aimed to evaluate efficacy and safety of fenoldopam in the management of hypertensive urgencies and emergencies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!